Literature DB >> 2539396

Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis.

H W Murray1, M J Oca, A M Granger, R D Schreiber.   

Abstract

Although directly microbicidal, pentavalent antimony has failed as treatment for visceral leishmaniasis in patients who also have AIDS or are receiving immunosuppressive therapy. To define the role of T cells in the successful host response to chemotherapy, we examined the efficacy of pentavalent antimony (sodium stibogluconate, Pentostam) in normal and T cell-deficient BALB/c mice infected with Leishmania donovani. In euthymic (nu/+) mice, single injections of 250 and 500 mg/kg of Pentostam induced the killing of 67% and 89% of intracellular liver amastigotes, respectively. In contrast, in athymic nude (nu/nu) mice, up to three injections of 500 mg/kg achieved no L. donovani killing and did not retard visceral parasite replication. Once nude mice were reconstituted with nu/+ spleen cells, however, Pentostam exerted strong leishmanicidal activity, an effect that appeared to be transferred by either L3T4+ or Lyt-2+ cells. Responsiveness to chemotherapy could also be induced by providing nude mice with either interferon-gamma or interleukin 2 alone. The absence of this T cell- and probably lymphokine-dependent mechanism is a likely explanation for treatment failures in immunocompromised patients infected with L. donovani and perhaps other systemic intracellular pathogens as well.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539396      PMCID: PMC303815          DOI: 10.1172/JCI114009

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  East African kalazar with special reference to the pathology, prophylaxis and treatment.

Authors:  P E MANSON-BAHR
Journal:  Trans R Soc Trop Med Hyg       Date:  1959-03       Impact factor: 2.184

2.  In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii.

Authors:  S D Sharma; J M Hofflin; J S Remington
Journal:  J Immunol       Date:  1985-12       Impact factor: 5.422

3.  Regulation of IFN-gamma induction in human peripheral blood cells by exogenous and endogenously produced interleukin 2.

Authors:  J Vilcek; D Henriksen-Destefano; D Siegel; A Klion; R J Robb; J Le
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

4.  Human monocyte activation for cytotoxicity against intracellular Leishmania donovani amastigotes: induction of microbicidal activity by interferon-gamma.

Authors:  D L Hoover; C A Nacy; M S Meltzer
Journal:  Cell Immunol       Date:  1985-09       Impact factor: 4.868

5.  Production of and in vitro response to interleukin 2 in the acquired immunodeficiency syndrome.

Authors:  H W Murray; K Welte; J L Jacobs; B Y Rubin; R Mertelsmann; R B Roberts
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

Review 6.  The immunobiology of leishmaniasis.

Authors:  R D Pearson; D A Wheeler; L H Harrison; H D Kay
Journal:  Rev Infect Dis       Date:  1983 Sep-Oct

7.  A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya.

Authors:  J D Chulay; S M Bhatt; R Muigai; M Ho; G Gachihi; J B Were; C Chunge; A D Bryceson
Journal:  J Infect Dis       Date:  1983-07       Impact factor: 5.226

8.  Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis.

Authors:  E M Carvalho; R Badaró; S G Reed; T C Jones; W D Johnson
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

9.  Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma.

Authors:  H W Murray; G L Spitalny; C F Nathan
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

10.  Activation of human macrophages. Comparison of other cytokines with interferon-gamma.

Authors:  C F Nathan; T J Prendergast; M E Wiebe; E R Stanley; E Platzer; H G Remold; K Welte; B Y Rubin; H W Murray
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  38 in total

1.  Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.

Authors:  P Escobar; V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

Review 3.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

4.  Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.

Authors:  Alexander B Mullen; Catherine E Lawrence; Emma McFarlane; Xiao-Quing Wei; Katharine C Carter
Journal:  Immunology       Date:  2006-07-26       Impact factor: 7.397

5.  Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.

Authors:  Alex G Peniche; Yaneth Osorio; Adam R Renslo; Doug E Frantz; Peter C Melby; Bruno L Travi
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

6.  Visceral leishmaniasis in an HIV-infected patient: clinical features and response to treatment.

Authors:  S Fenske; H J Stellbrink; H Albrecht; H Greten
Journal:  Klin Wochenschr       Date:  1991-10-31

7.  Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.

Authors:  Jayati Mookerjee Basu; Ananda Mookerjee; Prosenjit Sen; Suniti Bhaumik; Pradip Sen; Subha Banerjee; Ksudiram Naskar; Soumitra K Choudhuri; Bhaskar Saha; Sanghamitra Raha; Syamal Roy
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 8.  The immunology of parasite infections in immunocompromised hosts.

Authors:  T Evering; L M Weiss
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

9.  A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Sara E J Cotterell; Tracey L Mynott; Asiya Tschannerl; Patricia M A Gorak-Stolinska; Paul M Kaye
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

10.  In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma.

Authors:  C L Karp; S H el-Safi; T A Wynn; M M Satti; A M Kordofani; F A Hashim; M Hag-Ali; F A Neva; T B Nutman; D L Sacks
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.